摘要
目的观察罗沙司他治疗慢性肾脏病(CKD)5期非透析糖尿病肾脏疾病(DKD)患者肾性贫血的疗效和安全性。方法纳入2019年5月至2021年1月于大连医科大学附属第一医院肾内科就诊的CKD5期非透析DKD患者28例,所有患者均未应用红细胞生成刺激剂。根据体重制定罗沙司他起始剂量,血红蛋白(Hb)靶目标为(100~120)g/L,观察24周,治疗期间监测临床指标,并记录相关不良反应。结果所有患者基线平均Hb为(72.9±13.5)g/L,罗沙司他治疗24周,平均Hb为(103.4±13.4)g/L,较基线上升(25.7±10.8)g/L,Hb达标率为60%;疗效不受基线铁代谢及炎症状态的影响;基线平均低密度脂蛋白胆固醇(LDL-c)为2.5(1.1,4.1)mmol/L,治疗24周,平均LDL-c为1.9(1.3,2.6)mmol/L,有显著降低(P<0.05)。结论CKD5期非透析DKD患者肾性贫血对罗沙司他治疗反应良好。
Objective To observe the efficacy and safety of Roxadustat in the treatment of renal anemia in patients with chronic kidney disease(CKD)stage 5 non-dialysis diabetic kidney disease(DKD).Methods Twenty-eight patients with CKD stage 5 non-dialysis DKD treated in the Department of Nephrology of the First Affiliated Hospital of Dalian Medical University from May 2019 to January 2021 were selected.All patients did not receive erythropoiesis stimulants.The initial dose of Roxadustat was determined according to the body weight,the hemoglobin(Hb)target was 100-120 g/L,and the observation period was 24 weeks.The clinical indicators were monitored during the treatment,and related adverse reactions were recorded.Results The average baseline Hb of all patients was(72.9±13.5)g/L.The average Hb was(103.4±13.4)g/L after 24 weeks of Roxadustat treatment,with an increase of(25.7±10.8)g/L from the baseline.The hemoglobin level of at least 100 g/L was reported in 60%of patients.The curative effect was not affected by baseline iron metabolism or inflammation status;baseline average low-density lipoprotein cholesterol(LDL-c)was 2.5(1.1,4.1)mmol/L,and after 24 weeks of treatment,the average LDL-c was 1.9(1.3,2.6)mmol/L,there being a significant decrease(P<0.05).Conclusion Patients with CKD stage 5 non-dialysis DKD and renal anemia respond well to Roxadustat treatment.
作者
康乐
周晶莹
郭夏楠
方明
KANG Le;ZHOU Jing-ying;GUO Xia-nan;FANG Ming(Department of Basic Medicine,Medical College of Dalian University,Dalian 116622,China;不详)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2022年第3期238-241,共4页
Chinese Journal of Practical Internal Medicine
基金
国家自然科学基金(82100735)。
